Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Lee’s Pharma Subsidiary In-Licenses Dyax Drug for China Use

publication date: Feb 8, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
CVie Therapeutics, a subsidiary of Hong Kong-based Lee's Pharma, has in-licensed China rights to Kalbitor®, a treatment for hereditary angioedema, from Dyax Corp. of the US. CVie will be responsible for securing regulatory approval of the drug in China. It has been marketed in the US since 2010. Lee’s markets western drugs for sale in mainland China; it also has an in-house R&D drug development operation. More details....

Stock Symbols: (HK: 00950) (NSDQ: DYAX)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...